ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,293.60
1.49%
Dow Jones
40,415.44
0.32%
Brent Oil
81.635
-0.78%
Bitcoin
68,046.74
-0.16%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. 4D Pharma PLC (LBPS)

  7. 4D Pharma PLC (LBPS) News

LBPS

4D Pharma (LBPS)

4D Pharma PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LBPS
DateTimeSourceHeadlineSymbolCompany
01/03/202312:10PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
11/15/20221:54PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
10/07/202210:59AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
09/30/20223:04PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
08/24/20224:44PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
07/19/202211:49AMEdgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LBPS4D Pharma PLC
07/05/20222:07PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
06/29/20222:26PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
06/28/20221:50PMBusiness Wire4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqNASDAQ:LBPS4D Pharma PLC
06/27/20228:15AMTipRanksWhat Made Chardan Capital Downgrade 4d Pharma’s Stock?NASDAQ:LBPS4D Pharma PLC
06/24/20225:20PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
06/24/20223:32PMTipRanksLadenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to HoldNASDAQ:LBPS4D Pharma PLC
06/24/20222:41PMBusiness WireUpdate on Suspension of TradingNASDAQ:LBPS4D Pharma PLC
06/24/20229:20AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
06/01/20223:32PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
05/26/20225:30PMBusiness Wire4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LBPS4D Pharma PLC
05/19/20224:30PMBusiness Wire4D pharma to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:LBPS4D Pharma PLC
05/17/20227:00AMBusiness Wire4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceNASDAQ:LBPS4D Pharma PLC
04/29/20226:34AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
03/31/20225:27PMBusiness Wire4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022NASDAQ:LBPS4D Pharma PLC
03/31/20226:25AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LBPS4D Pharma PLC
03/28/20225:29PMEdgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:LBPS4D Pharma PLC
03/23/20227:46AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LBPS4D Pharma PLC
03/23/20227:00AMBusiness Wire4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaNASDAQ:LBPS4D Pharma PLC
03/02/20225:26PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LBPS4D Pharma PLC
02/28/20224:34PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:LBPS4D Pharma PLC
02/23/20227:00AMBusiness Wire4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitNASDAQ:LBPS4D Pharma PLC
02/22/20227:00AMBusiness Wire4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseNASDAQ:LBPS4D Pharma PLC
02/18/20225:03PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
02/18/20225:03PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LBPS4D Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:LBPS

Your Recent History

USOTC
ITUP
Interups (CE)
USOTC
IDVV
International Endeavors (PK)
USOTC
MGON
Megola (PK)
NYSE
AMC
AMC Entertainment
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
CNNA
Cann American (CE)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
GRLT
Grillit (PK)
USOTC
NBRI
North Bay Resources (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
SHMP
NaturalShrimp (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved